Sight Sciences, Inc. Share Price
NASDAQ: SGHT | Small CapSight Sciences, Inc. Stock Performance
Open $7.93 | Prev. Close $7.67 | Circuit Range N/A |
Day Range $7.88 - $8.41 | Year Range $3.19 - $9.21 | Volume 28,439 |
Average Traded $8.23 |
Sight Sciences, Inc. Share Price Today
As of 14 August 2026, Sight Sciences, Inc.'s share price is $8.27. The stock opened at $7.93, compared to its previous close of $7.67. During today's trading session, Sight Sciences, Inc.'s share price traded between $7.88 and $8.41, with an average price of $8.15. Over the past 52 weeks, the stock has recorded a high of $9.21 and a low of $3.19. In terms of performance, Sight Sciences, Inc.'s share price has risen by 60.12% over the last six months and is up 103.19% on a year-on-year basis.
Sight Sciences, Inc. Share Price Chart
Sight Sciences, Inc. Stock Fundamentals & Key Indicators
Market Cap $431.27M | PE Ratio (TTM) -11.18 | Dividend Yield N/A |
EPS (TTM) $-0.74 | Revenue (TTM) $77.36M | Return On Equity (TTM) -60.10% |
Profit Margin -49.67% | Debt to Equity 0.17 | Quarterly Earnings Growth YoY 26.18% |
Sight Sciences, Inc. Quarterly Profit & Loss
All figures in USD
Sight Sciences, Inc. Annual Profit & Loss
All figures in USD
About Sight Sciences, Inc.
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases. The company operates in two segments, Surgical Glaucoma and Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeons to perform a comprehensive procedure indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, as well as for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and SION surgical instrument, a bladeless manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The company also provides TearCare system, a dry eye device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Sight Sciences, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $5.46 | $8.27 | +57.22% |
Jul 2026 | $5.47 | $5.26 | -2.77% |
Jun 2026 | $4.65 | $5.41 | +10.97% |
May 2026 | $4.14 | $4.88 | +19.49% |
Apr 2026 | $3.76 | $4.08 | +7.94% |
Mar 2026 | $5.20 | $3.78 | -26.82% |
Feb 2026 | $6.29 | $5.17 | -17.49% |
Jan 2026 | $8.13 | $6.26 | -20.86% |
Dec 2025 | $8.20 | $7.91 | -4.58% |
Nov 2025 | $5.09 | $8.29 | +63.51% |
Oct 2025 | $3.38 | $5.07 | +47.81% |
Sep 2025 | $3.96 | $3.43 | -15.72% |